Showing 3881-3890 of 9301 results for "".
- Abrocitinib Shows Efficacy in Chronic Hand Eczema in Phase II Trialhttps://practicaldermatology.com/news/abrocitinib-shows-efficacy-in-chronic-hand-eczema-in-phase-ii-trial/2486424/Abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor approved for atopic dermatitis, demonstrated significant efficacy in patients with chronic hand eczema (CHE) of diverse etiologies in a Phase II randomized trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting.
- Oral STAT6 Degrader KT-621 Shows Early Promise in Atopic Dermatitishttps://practicaldermatology.com/news/oral-stat6-degrader-kt-621-shows-early-promise-in-atopic-dermatitis/2486423/A first-in-class oral STAT6 degrader, KT-621, demonstrated early clinical activity, robust biomarker suppression, and a favorable safety profile in adults with moderate-to-severe atopic dermatitis (AD), according to Phase 1b data presented by Mahta Mortezavi, MD, at the American Academy of Dermat
- Amlitelimab Shows Efficacy Across Phase 3 AD Trialshttps://practicaldermatology.com/news/amlitelimab-shows-efficacy-across-phase-3-ad-trials/2486422/Late-breaking Phase 3 data presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting demonstrated that amlitelimab, a nondepleting anti–OX40 ligand (OX40L) antibody, significantly improved disease severity and symptoms in patients with moderate-to-severe atopic dermatitis (AD), b
- MG-K10 Shows Sustained Efficacy in Atopic Dermatitis Through 52 Weekshttps://practicaldermatology.com/news/mg-k10-shows-sustained-efficacy-in-atopic-dermatitis-through-52-weeks/2486421/A long-acting anti–IL-4 receptor alpha monoclonal antibody, MG-K10, demonstrated sustained efficacy and a favorable safety profile through 52 wee
- Litifilimab Advances CLE Treatment With Positive Phase 2 Datahttps://practicaldermatology.com/news/litifilimab-advances-cle-treatment-with-positive-phase-2-data/2486419/Late-breaking data from the Phase 2 AMETHYST Part A trial presented at the American Academy of Dermatology (AAD) 2026 Annual Meeting show that litifilimab, a monoclonal antibody targeting blood dendritic cell antigen 2 (BDCA2), improved disease activity in patients with cutaneous lupus erythemato
- GLP-1 Receptor Agonists Show Complex, Evolving Role in Alopecia Areatahttps://practicaldermatology.com/news/glp-1-receptor-agonists-show-complex-evolving-role-in-alopecia-areata/2486415/The emerging and sometimes contradictory relationship between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and hair disorders, particularly alopecia areata, was the subject of a talk by Natasha Atanaskova Mesinkovska, MD, PhD, at the 2026 American Academy of Dermatology (AAD) Annual Meet
- Study Links MRGPRX3 Expression to Chronic Pruritus in PN and ADhttps://practicaldermatology.com/news/study-links-mrgprx3-expression-to-chronic-pruritus-in-pn-and-ad/2486413/In a prospective analysis of skin biopsies, investigators reported significantly elevated cutaneous MRGPRX3 expression in lesional prurigo nodularis (PN) and atopic dermatitis (AD), alongside a notable association between MRGPRX3-related gene mutations and Black pa
- What New Secukinumab Data Mean for HS Patients: A Q&A with Dr. April Armstronghttps://practicaldermatology.com/news/what-new-secukinumab-data-mean-for-hs-patients-a-qa-with-dr-april-armstrong/2486412/In the following Q&A, Dr. April Armstrong, professor and chief of dermatology at UCLA and a study coauthor, talks with Practical Dermatology about the importance of new secukinumab data for patients with hidradenitis suppurativa (HS). Speaking on UCB's recently announced top
- Study: Dermatologists Rarely Prescribe GLP-1 Agents in Psoriasis, HS Cohorthttps://practicaldermatology.com/news/study-dermatologists-rarely-prescribe-glp-1-agents-in-psoriasis-hs-cohort/2486411/A new retrospective review identified a significant gap in care between eligibility for glucagon-like peptide-1 receptor agonists (GLP-1RAs) and real-world utilization among patients with psoriasis and hidradenitis suppurativa (HS).
- Air Pollution Linked to Increased Psoriasis Burden: Meta-Analysishttps://practicaldermatology.com/news/air-pollution-linked-to-increased-psoriasis-burden-meta-analysis/2486409/New research presented at AAD 2026 suggests airborne pollutant particulate matter less than 2.5 microns in diameter (PM2.5), PM10, and NO2 showed the most consistent positive associations with psoriasis incidence in severity, and health care utilization.